Streetwise Live! Presents Algernon Pharmaceuticals on 01/27/2022. Learn More

Sector Expert: Carol Werther

H.C. Wainwright & Co.

Prior to joining H.C. Wainwright, Carol Werther worked as a biotechnology consultant for several firms, including Winslow Management and Rx Capital. She has also held senior biotechnology analyst positions at Summer Street Research Partners, Think Equity and Adams Harkness & Hill. Ms. Werther was recognized by The Wall Street Journal's "Best on the Street Survey" in 2000 and 2001. She received an MBA from New York University, Stern School of Business, and holds an MS and BS in nutrition sciences from the University of Alabama in Birmingham and Cornell University, respectively.

Recent Interviews

Being Selective in Biotech: Carol Werther (3/1/12)

In an industry steeped in complex research and speculative drug development, successful biotech investing requires real sophistication. Senior Biotechnology Analyst Carol Werther of Boston-based Summer Street Research Partners brings her experience to bear on the trinity of unmet needs, reimbursement and what physicians are willing to support with their prescription pads. In this exclusive interview with The Life Sciences Report, Werther shares her high-percentage picks that present opportunities for significant returns.

Recent Quotes

— Carol Werther, H.C. Wainwright & Co. (6/7/16)
more >

"LPTN is attracting talented employees who will add to the early development of new product candidates and strengthen clinical progress."

— Carol Werther, Summer Street Research Partners (4/17/13)
more >

"We are reiterating our Buy rating on LPTN."

— Carol Werther, Summer Street Research Partners (1/4/13)
more >

"IMUC is significantly undervalued."

— Carol Werther, Summer Street Research Partners (7/28/11)
more >

Due to permission requirements, not all quotes are shown.